Castle Biosciences Inc (CSTL)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.04B
Last updated: Nov 17, 2026 at 11:05 AM ET
Castle Biosciences Inc (CSTL) Stock Forecast
Analysts expect Castle Biosciences (CSTL) to earn -$0.85 per share in the fiscal year ending Dec 31, 2026, on revenue of $392.28M. Of 10 analysts, 10 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 10 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 10.6%.
- Fiscal year ending Dec 31, 2026
- -$0.85
- EPS consensus, revenue $392.28M
- Fiscal year ending Dec 31, 2027
- -$0.68
- EPS consensus, revenue $434.04M
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.85 | -$0.93 to -$0.74 | 7 | $392.28M | $390.18M to $397.30M | 9 |
| Dec 31, 2027 | -$0.68 | -$1.33 to -$0.11 | 8 | $434.04M | $401.80M to $487.50M | 10 |
Quarterly Estimates
The EPS consensus falls from -$0.16 for the quarter ending Dec 31, 2026 to -$0.31 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.16 | -$0.39 to $0.00 | 12 | $104.66M | $98.10M to $112.56M | 12 |
| Mar 31, 2027 | -$0.31 | -$0.46 to -$0.18 | 6 | $100.99M | $92.20M to $107.20M | 8 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 6 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.27.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.85 | -$1.25 | -$1.27 | -$1.27 | -$1.27 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.68 | -$0.94 | -$0.94 | -$0.99 | -$0.99 | N/A |
| Quarter ending Mar 31, 2027 | -$0.31 | -$0.39 | -$0.40 | -$0.42 | -$0.42 | N/A |
Frequently Asked Questions About CSTL
What is the CSTL stock forecast?
Consensus analyst estimates put Castle Biosciences's EPS at -$0.85 for the fiscal year ending Dec 31, 2026, on revenue of $392.28M. The consensus rating from 10 analysts is Buy.
How do analysts rate CSTL stock?
Of 10 analysts covering Castle Biosciences, 0 rate it Strong Buy, 10 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CSTL next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.85, with estimates from -$0.93 to -$0.74 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.68, with estimates from -$1.33 to -$0.11 from 8 analysts.
What revenue do analysts expect from Castle Biosciences next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $392.28M, with estimates from $390.18M to $397.30M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $434.04M, with estimates from $401.80M to $487.50M.
How many analysts cover CSTL?
10 analysts rate Castle Biosciences stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CSTL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts